Fol. Biol. 2005, 51, 3-11
https://doi.org/10.14712/fb2005051010003
Expression of CD44v6 Correlates with Cell Proliferation and Cellular Atypia in Urothelial Carcinoma Cell Lines 5637 and HT1197
References
1. , G., Ross, J. A., Guy, K. (1998) Forms and functions of CD44. Immunology 93, 139-148.
<https://doi.org/10.1046/j.1365-2567.1998.00431.x>
2. , S., Tarin, D. (1998) Current status of CD44 variant isoforms as cancer diagnostic markers. Histopathology 32, 1-6.
<https://doi.org/10.1046/j.1365-2559.1998.00262.x>
3. , S., Urquidi, V., Tarin, D. (1999) CD44 cell adhesion molecules. J. Clin. Pathol. Mol. Pathol. 52, 189-196.
<https://doi.org/10.1136/mp.52.4.189>
4. , D. C., Fawcet, J., Walch, M. D., Reeder, J. A., Simmons, D. L., Antalis, T. M. (1996) Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br. J. Cancer 74, 342-351.
<https://doi.org/10.1038/bjc.1996.364>
5. , R. L., Pu, Y. S., Hsieh, T. S., Chu, J. S., Lee, W. J. (1995) Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J. Urol. 153, 2025-2028.
<https://doi.org/10.1016/S0022-5347(01)67395-6>
6. , E., Charchanti, A., Stavropoulos, N., Athanassiou, E., Bafa, M., Agnantis, N. J. (2002) Expression of cathepsin D in urothelial carcinoma of urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB2 and the proliferation indices. Anticancer Res. 22, 3383-3388.
7. , M., Itoh, Y., Chiba, T., Mori, H., Okada, A., Kinoh, H., Seiki, M. (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J. Cell. Biol. 153, 893-904.
<https://doi.org/10.1083/jcb.153.5.893>
8. , G., Rodriguez, I., Jorcano, J. L., Vassalli, P., Stamenkovic, I. (1997) Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. 11, 996-1007.
<https://doi.org/10.1101/gad.11.8.996>
9. , M., Mathew, T. C., Makar, R. R., Sonia, L., Abul, H., Asfar, S., Al-Sayer, H., Dashti, H. M., Al-Bader, A. (2002) Expression of CD44s in human colorectal cancer. Path. Oncol. Res. 8, 170-174.
<https://doi.org/10.1007/BF03032390>
10. , P., Aaltoma, S., Kosma, V.-M., Ala-Opas, M., Eskelinen, M. (1998) Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J. Pathol. 186, 157-164.
<https://doi.org/10.1002/(SICI)1096-9896(1998100)186:2<157::AID-PATH169>3.0.CO;2-M>
11. , C. R., Terpe, H. J., Stauder, R., Marston, W. L., Stark, H., Gunthert, U. (1994) Expression and modulation of CD44 variant isoforms in humans. J. Cell. Biol. 124, 71-82.
<https://doi.org/10.1083/jcb.124.1.71>
12. , V., Elleder, M. (1980) Demonstration of enzymes in cells cultured on semipermeable membrane in a double chamber. Histochemistry 65, 325-327.
<https://doi.org/10.1007/BF00493183>
13. , T. A., Harrison, G., Mansel, R. E., Jiang, W. G. (2003) The role of the CD44/ezrin complex in cancer metastasis. Crit. Rev. Oncol. Hematol. 46, 165-186.
<https://doi.org/10.1016/S1040-8428(02)00172-5>
14. , T., Mitomi, H., Hara, A., Yanagisawa, N., Yoshida, T., Tsuruta, O., Okayasu, I. (2000) Decreased expression of CD44, alpha-catenin, and deleted colon carcinoma and altered expression of beta-catenin in ulcerative colitisassociated dysplasia and carcinoma, as compared with sporadic colon neoplasms. Cancer 89, 733-740.
<https://doi.org/10.1002/1097-0142(20000815)89:4<733::AID-CNCR3>3.0.CO;2-#>
15. , M., Heicappell, R., Habermann, F., Kaufmann, M., Steiner, U., Miller, K. (1997) Expression of CD44V2 in transitional cell carcinoma of the urinary bladder and in urine. Urol. Res. 25, 187-192.
<https://doi.org/10.1007/BF00941981>
16. , V. N., Mirejovsky, T., Melinova, L., Mandys, V. (2000) CD44 and its v6 spliced variant in lung carcinomas: Relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 47, 400-408.
17. , H., Sherman, L., Herrlich, P. A. (2003) CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell. Biol. 4, 33-45.
<https://doi.org/10.1038/nrm1004>
18. , Z., Jothy, S. (1997) CD44 and the adhesion of neoplastic cells. J. Clin. Pathol. 50, 57-71.
19. , M., Hashimura, M., Machida, D., Okayasu, I. (1999) Downregulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumours. J. Pathol. 187, 173-83.
<https://doi.org/10.1002/(SICI)1096-9896(199901)187:2<173::AID-PATH207>3.0.CO;2-4>
20. , G. R., Bell, M. V., Jackson, D. G., Cornelis, F. B., Gerth, U., Bell, J. I. (1992) Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA 89, 12160-12164.
<https://doi.org/10.1073/pnas.89.24.12160>
21. , A., Gote, L., Nagarkatti, M., Nagarkatti, P. S. (1991) T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. Proc. Natl. Acad. Sci. USA 88, 7877-7881.
<https://doi.org/10.1073/pnas.88.17.7877>
22. , L., Wainwright, D., Ponta, H., Herrlich, P. (1998) A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes Dev. 12, 1058-1071.
<https://doi.org/10.1101/gad.12.7.1058>
23. , T. P., Zeng, C., Nocks, A., Stamenkovic, I. (1998) Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J. Cell. Biol. 140, 431-446.
<https://doi.org/10.1083/jcb.140.2.431>
24. , R. J. S., Mangham, D. C. (1998) The normal structure and function of CD44 and its role in neoplasia. J. Clin. Pathol. Mol. Pathol. 51, 191-200.
<https://doi.org/10.1136/mp.51.4.191>
25. , J., Trejdosiewicz, L., Smith, B., Selby, P. (1995) Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int. J. Cancer 62, 449-456.
<https://doi.org/10.1002/ijc.2910620415>
26. , T., Gorham, H., Yoshida, K., Bolodeoku, J., Nargund, V., Cranston, D., Goodison, S., Tarin, D. (1996) Progressive loss of CD44 gene expression in invasive bladder cancer. Am. J. Pathol. 149, 873-882.
27. V., Hauri, D., Schmid U., Ackermann, D., Maurer, R., Alund, G., Knönagel, H., Rist, M., Gasser, T.C., Sauter, G., Roth, J. (1999) Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am. J. Pathol. 155, 1427-1432.
<https://doi.org/10.1016/S0002-9440(10)65455-7>
28. , M. J., Di Como, C. J., Lu, M-L., Charytonowicz, E., Verbel, D., Ince, T. A., McKeon, F. D., Cordon-Cardo, C. (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161, 1199-1206.
<https://doi.org/10.1016/S0002-9440(10)64396-9>
29. , K., Rubenthiran, U., Jothy, S. (2003) Motility of colon cancer cells: modulation by CD44 isoform expression. Exp. Mol. Pathol. 75, 124-130.
<https://doi.org/10.1016/S0014-4800(03)00053-4>
